Ranjani Somayaji, David R Luke, Arthur Lau, Rahmet Guner, Ŏ Fehmi Tabak, Mark Hepokoski, Nancy Gardetto, Steven A Conrad, Sunil D Kumar, Kalyan Ghosh, Stephen M Robbins, Donna L Senger, Daisy Sun, Rachel K S Lim, Jonathan Liu, Fatma Eser, Ridvan Karaali, Alain Tremblay, Daniel Muruve
OBJECTIVE: Dipeptidase-1 (DPEP-1) is a recently discovered leucocyte adhesion receptor for neutrophils and monocytes in the lungs and kidneys and serves as a potential therapeutic target to attenuate inflammation in moderate-to-severe COVID-19. We aimed to evaluate the safety and efficacy of the DPEP-1 inhibitor, LSALT peptide, to prevent specific organ dysfunction in patients hospitalised with COVID-19. DESIGN: Phase 2a randomised, placebo-controlled, double-blinded, trial...
March 15, 2024: BMJ Open